




AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

NICE and AWMSG Approved Medicines
Formulary Status Report

(From 01 January 2025 to 31 December 2025)



BACKGROUND

The seven health boards and one NHS trust in Wales, are required to make recommended medicines available as soon as is reasonably practicable, and certainly within 60 calendar days of the publication of the decision. For National Institute for Health and Care Excellence (NICE) recommendations, a medicine should be available no later than 60 calendar days after the first publication of the Final Appraisal Determination (FAD)/Final Draft Guideline (FDG), or the Final Evaluation Determination (FED) for Highly Specialised Technologies (HSTs). For All Wales Medicines Strategy Group (AWMSG) recommendations, a medicine should be available no later than 60 calendar days after ratification of the recommendation by the Welsh Government. Occasionally the start of the 60-day timescale may be delayed. In such circumstances the 'Start date' aligns with the date that the delaying reason has been resolved. NICE and AWMSG may recommend an entirely new medicine, or a new use of an existing medicine to treat a different condition, for routine use in the NHS. Although recommended medicines should be made available within 60 days of recommendation, the sooner they are available, the sooner they can be prescribed where clinically appropriate.

A formulary is an official list of medicines which may be prescribed within the health board or NHS trust to treat patients. Until a medicine is added to the formulary, prescribers may not be aware that it is available for use. Velindre University NHS Trust treats certain types of cancers only; the report therefore only takes account of those medicines clinically appropriate for inclusion on the trust formulary.

This document reports on the formulary status of medicines recommended for use within NHS Wales by NICE and AWMSG. All medicines listed in this report were recommended over a 12-month period, commencing at least 14 months prior to the publication of this report. This is to account for the generally applicable 60-day period available to health boards and NHS trust to add these medicines to their formularies. Where an extended timescale has been authorised the data reporting system has been adapted to accommodate the variations.

SOURCE OF INFORMATION

This report has been compiled through an analysis of health board and trust submitted data to the All Wales Therapeutics and Toxicology Centre (AWTTC).

In exceptional circumstances some medicines data have been removed from this report in light of specific factors outside the control of health boards and NHS trust.

Data extracted 18/05/2026






Key		On formulary within required timescale		On formulary outside of required timescale		Not on formulary but within required timescale
		Not on formulary and outside of required timescale		Not applicable to Velindre		

Table 1. Formulary status for NICE and AWMSG approved medicines

Reference	Medicine Name	Abbreviated Indication	Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID6336 (TA1040)	Olaparib	Breast cancer	09 Jan 25								
ID1001 (TA1034)	Anhydrous sodium thiosulfate	Ototoxicity	13 Jan 25								
ID4024 (TA1031)	Vamorolone	Duchenne muscular dystrophy	14 Jan 25								
ID6280 (TA1045)	12 SQ-HDM	Allergic rhinitis	31 Jan 25								
ID6404 (TA1041)	Durvalumab	Lung cancer	03 Feb 25								
2566	Emtricitabine/tenofovir alafena..	HIV	17 Feb 25								
ID1651 (TA1050)	Fenfluramine	Lennox-Gastaut syndrome	20 Feb 25								
ID3887 (TA1048)	Lisocabtagene maraleucel	B-cell lymphoma	20 Feb 25								
ID6405 (TA1049)	Blinatumomab	Lymphoblastic leukaemia	25 Feb 25								
ID4015 (TA1003)	Exagamglogene autotemcel	Transfusion-dependent beta-thalassaemia	11 Mar 25								
ID4016 (TA1044)	Exagamglogene autotemcel	Sickle cell disease	11 Mar 25								
ID6263 (TA1053)	Cladribine	Multiple sclerosis	12 Mar 25								
ID3982 (TA1057)	Relugolix-estradiol-norethister..	Endometriosis	13 Mar 25								
ID6130 (HST33)	Leniolisib	Phosphoinositide 3-kinase delta syndrome	14 Mar 25								
ID6302 (TA1005)	Futibatinib	Advanced cholangiocarcinoma	20 Mar 25								
ID6170 (TA1051)	Efanesoctocog alfa	Haemophilia A	24 Mar 25								
ID6340 (TA1056)	Molnupiravir	COVID-19	28 Mar 25								
ID6426 (TA1064)	Dostarlimab	Endometrial cancer	11 Apr 25								
ID6178 (TA1066)	Somapacitan	Growth hormone deficiency	16 Apr 25								
ID1136 (TA1065)	Ipilimumab	Colorectal cancer	28 Apr 25								
ID1136 (TA1065)	Nivolumab	Colorectal cancer	28 Apr 25								
ID3822 (TA993)	Burosumab	Hypophosphataemia	30 Apr 25								
ID6357 (TA1067)	Linzagolix	Endometriosis	01 May 25								
ID6334 (TA1059)	Brentuximab vedotin	Hodgkin lymphoma	14 May 25								
ID3963 (TA1070)	Spesolimab	Psoriasis	15 May 25								
ID6324 (TA1071)	Atezolizumab	Lung cancer	15 May 25								
ID6370 (TA1063)	Capivasertib	Breast cancer	15 May 25								
ID6225 (TA1036)	Elacestrant	Breast cancer	19 May 25								
ID1333 (TA1062)	Erdafitinib	Urothelial cancer	27 May 25								

Reference	Medicine Name	Abbreviated Indication	Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
5385	Ziconotide	Chronic pain	29 May 25								
6440	Guanfacine	ADHD	29 May 25								
6441	Abiraterone	Prostate cancer	29 May 25								
ID6244 (TA1080)	Mirikizumab	Crohn's disease	02 Jun 25								
ID6320 (TA1022)	Bevacizumab gamma	Wet age-related macular degeneration	02 Jun 25								
ID6411 (TA1075)	Dapagliflozin	Chronic kidney disease	03 Jun 25								
ID5120 (TA1043)	Osimertinib	Lung cancer	11 Jun 25								
ID6317	Durvalumab	Endometrial cancer	12 Jun 25								
ID6221 (TA1077)	Nemolizumab	Atopic dermatitis	18 Jun 25								
6561	Teriparatide	osteoporosis in men	20 Jun 25								
ID6342 (TA1073)	Marstacimab	Haemophilia A or B	23 Jun 25								
ID6392 (TA1081)	Zanubrutinib	Mantle cell lymphoma	27 Jun 25								
ID6274 (TA1079)	Fruquintinib	Colorectal cancer	03 Jul 25								
ID6293 (TA1042)	Selpercatinib	Lung cancer	04 Jul 25								
ID6328 (TA1060)	Osimertinib	Lung cancer	08 Jul 25								
ID6153 (TA1086)	Ribociclib	Breast cancer	18 Jul 25								
ID6462 (TA1087)	Betula verrucosa	Allergic rhinitis and/or conjunctivitis	21 Jul 25								
ID6308 (TA1074)	Sparsentan	Primary IgA nephropathy	23 Jul 25								
ID2725 (TA1090)	Tremelimumab	Hepatocellular carcinoma	29 Jul 25								
ID547 (TA1093)	Idebenone	Leber's hereditary optic neuropathy	08 Aug 25								
ID2725 (TA1090)	Durvalumab	Hepatocellular carcinoma	12 Aug 25								
ID6237 (ID1094)	Guselkumab	Ulcerative colitis	14 Aug 25								
ID6238 (TA1095)	Guselkumab	Crohn's disease	14 Aug 25								
ID5100 (TA1055)	Rucaparib	Ovarian, fallopian tube and peritoneal cancer	19 Aug 25								
ID3981 (TA1098)	Isatuximab	Multiple myeloma	04 Sept 25								
ID5073 (TA1099)	Durvalumab	Lung cancer	16 Sept 25								
ID6394 (TA1101)	Garadacimab	Hereditary angioedema	18 Sept 25								
ID4069 (TA1007)	Rucaparib	Ovarian, fallopian tube or peritoneal cancer	23 Sept 25								
ID6408 (TA1107)	Delgocitinib	Eczema	16 Oct 25								
ID6255 (TA1106)	Cabotegravir	HIV	17 Oct 25								
ID6452 (TA1109)	Darolutamide	Prostate cancer	24 Oct 25								
ID6378 (TA1110)	Abiraterone	Prostate cancer	30 Oct 25								
ID6372 (TA1085)	Vanzacaftor-tezacaftor-deutiva..	Cystic fibrosis	31 Oct 25								
ID6434 (TA1103)	Lorlatinib	Lung cancer	31 Oct 25								
ID6332 (TA1097)	Enfortumab vedotin	Urothelial cancer	07 Nov 25								

Reference	Medicine Name	Abbreviated Indication	Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID6332 (TA1097)	Pembrolizumab	Urothelial cancer	07 Nov 25								
ID6381 (TA1092)	Pembrolizumab	Endometrial cancer	07 Nov 25								
ID6202 (TA1113)	Glofitamab	Large B-cell lymphoma	14 Nov 25								
ID5082 (TA1114)	Talquetamab	Multiple myeloma	17 Nov 25								
ID6347 (TA1116)	Obecabtagene autoleucl	B-cell acute lymphoblastic leukemia	25 Nov 25								
ID6266 (TA1096)	Benralizumab	Eosinophilic granulomatosis	09 Dec 25								
ID6294 (TA1120)	Axitinib	Renal cell carcinoma	11 Dec 25								
ID6354 (TA1121)	Acoramidis	Amyloidosis cardiomyopathy	12 Dec 25								
ID6291 (TA1119)	Obinutuzamab	Chronic lymphocytic leukemia	16 Dec 25								
ID6291 (TA1119)	Venetoclax	Chronic Lymphocytic Leukamia	16 Dec 25								
ID6256 (TA1122)	Amivantamab	Non small cell lung cancer	18 Dec 25								
ID6256 (TA1122)	Lazertinib	Non small cell lung cancer	18 Dec 25								

End of Report